Search of: Open Studies | Interventional Studies | solid tumors | Adult | Phase II III IV - List Results - ClinicalTrials.gov

search results = 137 clinical trials

Possible results: genetic testing (as per Myriad site)

Simple chart: possibleresults1big.jpg (JPEG Image, 945x582 pixels)

Gene discovery may help guide breast cancer care | Reuters

California to set time limit to see doctors - washingtonpost.com

full free access: Early-onset breast cancer in a Lebanese family with Lynch syndrome due to MSH2 gene mutation

"Background: There are still controversies about the integration of breast cancer as a part of the disease spectrum in Lynch syndrome."

full free access: Type D personality in the general population: a systematic review of health status, mechanisms of disease, and work-related problems

"Type D personality in the general population: a systematic review of health status, mechanisms of disease, and work-related problems."

Jan 23, 2009: Authors' Reply: Dose-dense paclitaxel for advanced ovarian cancer – Authors' reply : The Lancet

Authors' explanation to Commentaries 1 & 2

Jan 23, 2009: Commentary (2nd of 2): Dose-dense paclitaxel for advanced ovarian cancer : The Lancet

Jan 23, 2009: Commentary (1 of 2): Dose-dense paclitaxel for advanced ovarian cancer : The Lancet

Note: may require registration (free):

Growth of aid and the decline of humanitarianism : The Lancet

updated 2010 - MSH2 (one of the Lynch Syndrome genes)

"People with mutations in the MSH2 gene have an increased risk of developing several other types of cancer (colorectal), including cancers of the endometrium (lining of the uterus), ovary, stomach, small intestine, liver, gallbladder duct, upper urinary tract, brain, and skin.
Some mutations in the MSH2 gene increase the likelihood of several uncommon skin tumors occurring in addition to colorectal cancer, a combination called Muir-Torre syndrome. These rare skin tumors include sebaceous adenomas and carcinomas, which occur in skin glands (sebaceous glands) that produce an oily substance called sebum. Multiple, rapidly growing skin tumors called keratoacanthomas may also occur, usually on sun-exposed areas.

Jan 5th, 2010 Q&A: Understanding and Managing Lynch Syndrome - Cancerwise | Cancer blog from M. D. Anderson Cancer Center

Basic overview

Kathryn Joosten: Talking About That Tough Subject

media item: Father's long crusade for answers

Note:  "In 2006, a respected cancer research charity started losing donors when it was mistaken for the CCRG following the W5 program."

Understanding the problem of inadequately staging of early ovarian cancer (subanalysis of ACTION trial)

CONCLUSIONS: Even in a randomised trial in which comprehensive surgical staging was strongly advised in the study protocol the majority of patients (66%) were incompletely staged. Factors relating to a lack of surgical skills attributed most to the number of incompletely staged patients, but insufficient knowledge of the tumour behaviour and routes of spread of ovarian cancer also contributed substantially to this problem. Multicentre trials recruiting patients from many institutes with small volume contribution to the study, run the risk of inadequate adherence to the study protocol.

Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey): Findings in Surgical Patients

Note: study of data from 2004

"Use of prophylaxis varied according to major surgery type from 86.0% for orthopedic surgery to 53.8% in urologic/gynecologic...."  "Conclusions: The majority of surgical patients are at high-risk for VTE. Despite long-standing recognition of the high-risk for VTE in surgical patients, thromboprophylaxis remains underutilized."

March 1, 2010 abstract: Conundrums in screening for cancer

Mini Review

Conundrums in screening for cancer

Anthony B. Miller *

Dalla Lana School of Public Health, University of Toronto, ON, Canada

email: Anthony B. Miller (ab.miller@sympatico.ca)

*Correspondence to Anthony B. Miller, Associate Director, Research, Dalla Lana School of Public Health, University of Toronto, Canada
This article is based upon the Joint International Journal of Cancer and Meyenburg-Stiftung Lectureship, delivered at Deutsches Krebsforschungszentrum, February 18, 2009.

Keywords

screening for cancer • breast cancer • cervix cancer • prostate cancer

Abstract

Screening for cancer has to be carefully organized for maximum effectiveness, and introduced in full understanding of the natural history of the disease. There are major potential harms as well as benefits from screening. The current state of art for breast, cervix and prostate cancer screening is reviewed, only for breast and cervix are policies of screening in the population justified.

---

Unique Canadian Program Teaches Students Stroke Care

Neoadjuvant Bevacizumab May Increase Serious Surgical Complications - OncologySTAT

Note: free access (sign up):
Neoadjuvant_Bevacizumab_May Increase Serious Surgical Complications

media article: Neoadjuvant Bevacizumab May Increase Serious Surgical Complications

"Most complications started in the immediate postoperative period, stuttered along, then worsened weeks later when bevacizumab was restarted, according to Dr. Golshan." "This observation caused one audience member to quip, “Perhaps these wounds, even though they may appear to be healed, should receive more respect and less bevacizumab.”"

media item: Breast cancer surgeons prefer to go it alone - Cancer Network

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer

"METHODS:: Patients with stage III/IV EOC received cyclophosphamide 750 mg/m(2), followed by a 24-hour infusion of paclitaxel 250 mg/m(2) and cisplatin 75 mg/m(2) on Day 2. Filgrastim began on Day 3 at 10 mug/kg daily for 9 days. Patients received 6 cycles of all drugs." CONCLUSIONS:: The studied regimen yielded a high response rate and encouraging overall survival."